Radar · Infectious Diseases in United States
Best Infectious Diseases Companies in United States
The 1010 best Infectious Diseases companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
By Riya SenguptaFinancials
1010companies tracked
$29.7Bdisclosed funding
1unicorns
622have raised
Ranking the top Infectious Diseases companies in the United States by disclosed equity funding and recent momentum, this directory tracks 1,010 firms carrying $29.7B in total disclosed capital. That's a serious pool. Moderna alone absorbed $2.8B of it, and CytoDyn and NovaBay Pharmaceuticals pulled in $250M and $220M respectively, with government bodies like HHS, NIH, and NIAID doing most of the heavy lifting as active investors. The revenue picture is more grounded: across 19 validated filers, median revenue sits at roughly $2M with a -7% YoY drift, but the combined pool still clears $1.3B. Insmed Inc drives a large share of that, booking $606M at +67% growth. Cubist Pharmaceuticals posted $238M and netted $40M, which is 20x the sector median net income. That kind of profitability spread tells you something real about where earnings concentrate.
So what's actually moving the space right now? Coverage is flat, but the equity inequality angle is drawing fresh attention, as is the push into neglected tropical diseases and tuberculosis reactivation. I'd watch those themes closely if you're evaluating which filers have durable revenue versus one-cycle spikes. Siga Technologies earned $95M in revenue but saw it drop 32% YoY, a reminder that infectious disease revenues can swing hard on contract timing and outbreak cycles. The one unicorn in the directory signals selective investor conviction, not broad sector euphoria.
Sources & further reading
- HIV specialists in short supply, especially in the South
- Let us not forget these tropical diseases
- Americans to be offered coronavirus vaccine boost starting next month
FLIAR INTELLIGENCE · INFECTIOUS DISEASES × UNITED STATES
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
59%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2014median founding year
1.1Mcombined LinkedIn audience
85%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Infectious Diseases companies in United States
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Moderna Developer of mRNA-based therapeutics for a wide range of diseases 82Tech top 11%Funding top 15%Market top 22%Partners top 25% All 12 signals ▾Techtop 11% Fundingtop 15% Markettop 22% Partnerstop 25% Talenttop 25% Newstop 31% Moattop 32% Patentstop 34% Globaltop 38% Innovationtop 39% Growthbottom 49% Fin. healthbottom 48% Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) rank vs industry peers · Fliar Intelligence Index 82/100 | $2.8B | 17 mo ago | Public | 1,312 | Robert Langer Co-Founder | 47 signals Earnings · Contracts · Leadership | 31 patents Patents concentrated in health & consumer products | 1 internship |
| 2 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 17 mo ago | Public | 75 | Gevorg Grigoryan Co-Founder & CTO | 6 signals IPO | 36 patents Patents concentrated in chemistry & materials | — |
| 3 | Insmed Developer of small molecule inhibitors for rare lung diseases 90Tech top 12%Funding top 18%Patents top 20%Market top 24% All 12 signals ▾Techtop 12% Fundingtop 18% Patentstop 20% Markettop 24% Moattop 24% Innovationtop 25% Producttop 28% Growthtop 33% Fin. healthtop 33% Newstop 40% Globaltop 42% Talentbottom 49% Tech: 63 technologies across 7/8 capability areas · Cloud: Cloudflare, Google Cloud Funding: Raised $452M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $452M | 13 mo ago | Public | 912 912 → 1,735 (+90%) · sector median +33% | Will Lewis CEO | 22 signals Earnings · Announcements · FDA approval | 636 patents Pulmonary anti-infective drug formulations and DPP1 inhibitor therapeutics | 1 internship |
| 4 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | Public | 12 12 → 23 (+92%) · sector median +33% | — | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH and immune‑modulating therapies | 1 partnership |
| 5 | Aligos Therapeutics Developer of therapies to treat hepatologic diseases and viral infections 50Patents top 12%Innovation top 16%Funding top 26%Moat top 35% All 12 signals ▾Patentstop 12% Innovationtop 16% Fundingtop 26% Moattop 35% Partnerstop 40% Techtop 42% Talenttop 45% Globaltop 46% Newstop 47% Marketbottom 46% Growthbottom 32% Fin. healthbottom 25% Patents: 503 patents matched (strict assignee match) · 389 filings since 2022 vs 114 in 2017-21 Innovation: 503 patents (top 5% of patent-holders) · 389 filings since 2022 vs 114 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $225M | 16 mo ago | Public | 70 70 → 99 (+41%) · sector median +33% | Lawrence Blatt CEO | 8 signals ▼65% Earnings · Contracts | 503 patents RNA interference therapeutics and PD‑L1 immuno‑oncology using heterocyclic siRNA delivery compounds | — |
| 6 | NovaBay Pharmaceuticals Developer of eye care and wound care products 32Funding top 21%Product top 35%News top 46%Talent bottom 49% All 10 signals ▾Fundingtop 21% Producttop 35% Newstop 46% Talentbottom 49% Moatbottom 44% Marketbottom 43% Techbottom 41% Growthbottom 40% Globalbottom 38% Fin. healthbottom 37% Funding: Raised $220M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Product: 0 product launch events in 12 mo · Company stage: Public rank vs industry peers · Fliar Intelligence Index 32/100 | $220M | 5 mo ago | Public | 33 33 → 38 (+15%) · sector median +33% | Justin Hall CEO | 5 signals ▼62% M&A · Regulatory · Announcements | — | — |
| 7 | CytoVale Microfluidic-based biomarkers for the early detection of sepsis 60Funding top 19%Product top 21%Patents top 26%Innovation top 32% All 10 signals ▾Fundingtop 19% Producttop 21% Patentstop 26% Innovationtop 32% Moattop 32% Techtop 38% Growthtop 47% Marketbottom 42% Globalbottom 42% Newsbottom 21% Funding: Raised $207M across 14 rounds · 14 rounds over 13 yrs (1.1/yr) Product: 4 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 60/100 | $207M | 20 mo ago | Series D | 58 58 → 120 (+107%) · sector median +33% | — | — | 38 patents Point-of-care diagnostic platforms for immune activity and sepsis monitoring | — |
| 8 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 9 mo ago | Funding Raised | 77 | — | — | 134 patents Malaria vaccine production, sporozoite cryopreservation, and vector storage technologies | — |
| 9 | Microbiotix Biopharmaceutical company combating serious infectious diseases and multi-drug resistant pathogens 32Patents top 20%Funding top 24%Innovation top 28%Moat top 41% All 8 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 28% Moattop 41% Globalbottom 38% Marketbottom 29% Newsbottom 17% Techbottom 16% Patents: 143 patents matched (strict assignee match) · 43 filings since 2022 vs 33 in 2017-21 Funding: Raised $152M across 61 rounds · 61 rounds over 25 yrs (2.4/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $152M | 13 mo ago | Funding Raised | 23 | — | — | 143 patents Discovery and development of antimicrobial small‑molecule therapeutics (antifungal, antibacterial, antiviral). | — |
| 10 | Clear Labs Provider of food safety technologies for the identification of pathogens 60Patents top 19%Funding top 22%Innovation top 28%Moat top 28% All 10 signals ▾Patentstop 19% Fundingtop 22% Innovationtop 28% Moattop 28% Growthtop 32% Talenttop 41% Globalbottom 44% Marketbottom 40% Techbottom 33% Newsbottom 21% Patents: 79 patents matched (strict assignee match) · 40 filings since 2022 vs 25 in 2017-21 Funding: Raised $141M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $141M | 18 mo ago | Series D | 55 55 → 85 (+55%) · sector median +33% | Sasan Amini Co-Founder & CEO | — | 79 patents Automated liquid handling and cartridge systems for nucleic‑acid sequencing sample preparation | — |
| 11 | Sherlock Provider of a diagnostic platform for DNA and RNA detection 62Growth top 13%Funding top 22%Talent top 28%Moat top 41% All 9 signals ▾Growthtop 13% Fundingtop 22% Talenttop 28% Moattop 41% Patentsbottom 46% Innovationbottom 41% Marketbottom 39% Globalbottom 37% Newsbottom 34% Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $111M | 12 mo ago | Acquired | 33 | David Walt Co-Founder | — | 5 patents Remote health monitoring systems that detect critical vitals and trigger emergency interventions | — |
| 12 | Osteal Therapeutics Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections 29Funding top 19%Moat top 38%Talent bottom 49%Global bottom 37% All 5 signals ▾Fundingtop 19% Moattop 38% Talentbottom 49% Globalbottom 37% Marketbottom 31% Funding: Raised $111M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $111M | 8 mo ago | Series D | 13 | David Thompson Chairman and Chief Executive Officer | — | — | 9 job openings |
| 13 | VenatoRx US-based, clinical stage biotech developing beta-lactamase inhibitors for DR infections 50Funding top 19%Product top 25%Innovation top 34%Growth top 39% All 9 signals ▾Fundingtop 19% Producttop 25% Innovationtop 34% Growthtop 39% Moattop 39% Marketbottom 40% Globalbottom 37% Newsbottom 27% Techbottom 25% Funding: Raised $103M across 35 rounds · 35 rounds over 13 yrs (2.7/yr) Product: 8 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 50/100 | $103M | 12 mo ago | Series C | 80 | — | — | — | — |
| 14 | Evofem Developer of sexual and reproductive health therapeutics 50Funding top 24%Product top 30%Moat top 38%Patents top 43% All 12 signals ▾Fundingtop 24% Producttop 30% Moattop 38% Patentstop 43% Fin. healthtop 46% Innovationtop 48% Markettop 49% Growthbottom 49% Talentbottom 49% Techbottom 43% Newsbottom 41% Globalbottom 40% Funding: Raised $100M across 15 rounds · 15 rounds over 17 yrs (0.9/yr) Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 11 mo ago | Public | 126 | Saundra Pelletier CEO ► Phexxi ► Solosec | 3 signals ▼79% Earnings · M&A | 60 patents Vaginal film drug delivery systems for contraception, STI prevention, and antimicrobial microbicides | 1 partnership |
| 15 | AN2 Therapeutics Developer of drugs for treating infectious disease 45Funding top 19%Talent top 38%Moat top 48%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 38% Moattop 48% Marketbottom 42% Globalbottom 32% Newsbottom 24% Funding: Raised $92.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $92M | 3 mo ago | Public | 35 35 → 37 (+6%) · sector median +33% | Eric Easom Co-Founder & CEO & President | — | — | — |
| 16 | Mapp Biopharmaceutical Develops novel pharmaceuticals for infectious diseases, focusing on global health 50Funding top 29%Patents top 35%Growth top 39%Innovation top 42% All 10 signals ▾Fundingtop 29% Patentstop 35% Growthtop 39% Innovationtop 42% Moattop 45% Producttop 46% Talentbottom 49% Marketbottom 47% Globalbottom 38% Techbottom 36% Funding: Raised $91.9M across 29 rounds · 29 rounds over 22 yrs (1.3/yr) Patents: 44 patents matched (strict assignee match) · 17 filings since 2022 vs 22 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $92M | 13 mo ago | Funding Raised | 62 62 → 74 (+19%) · sector median +33% | Kevin Whaley CEO | — | 44 patents Therapeutic monoclonal antibodies targeting emerging viral pathogens (e.g., Ebola, henipavirus, hantavirus, RSV). | — |
| 17 | Curevo Developer of vaccines for the treatment of various diseases 29Funding top 25%Talent top 41%Moat top 43%Patents top 48% All 9 signals ▾Fundingtop 25% Talenttop 41% Moattop 43% Patentstop 48% Techtop 50% Innovationbottom 45% Globalbottom 39% Marketbottom 22% Newsbottom 18% Funding: Raised $86.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $86M | 15 mo ago | Series B | 8 | George Simeon CEO | — | 3 patents Herpes zoster and combination vaccine formulations for immunogenic protection | — |
| 18 | Pattern Bioscience Provider of multiple diagnostics platforms for infectious diseases 60Patents top 20%Funding top 25%Innovation top 26%Moat top 32% All 10 signals ▾Patentstop 20% Fundingtop 25% Innovationtop 26% Moattop 32% Growthtop 37% Talenttop 38% Techbottom 46% Marketbottom 38% Globalbottom 38% Newsbottom 22% Patents: 58 patents matched (strict assignee match) · 42 filings since 2022 vs 16 in 2017-21 Funding: Raised $68.0M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $68M | 10 mo ago | Series C | 58 58 → 77 (+33%) · sector median +33% | Ross Johnson Co-Founder | — | 58 patents Microfluidic single-cell analysis platforms for diagnostic and phenotypic screening | 1 award |
| 19 | Integral Molecular Optimizing Membrane Protein Expression for new drug and antibody discovery 67Tech top 22%Patents top 22%Innovation top 27%Funding top 28% All 9 signals ▾Techtop 22% Patentstop 22% Innovationtop 27% Fundingtop 28% Growthtop 37% Moattop 41% Talentbottom 49% Marketbottom 42% Globalbottom 36% Tech: 53 technologies across 6/8 capability areas · Cloud: Cloudflare Patents: 103 patents matched (strict assignee match) · 42 filings since 2022 vs 26 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $57M | 14 mo ago | Funding Raised | 78 78 → 127 (+63%) · sector median +33% | Ben Doranz President and CEO | — | 103 patents Therapeutic antibodies targeting cancer antigens (claudin‑6, claudin‑18.2, GPRC5D, P2X) | 1 launch |
| 20 | Latus Developer of gene therapy medicines for neurological diseases 35Funding top 26%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $54.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | Series A | — | P Ghoroghchian CEO | — | — | — |
| 21 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 7 mo ago | Series B | 31 | Jeff Galvin Chief Executive Officer | — | 228 patents Non-integrating viral vectors for gene delivery and HIV immunotherapy, plus gamma‑delta T‑cell activation | — |
| 22 | Therapeutic Systems Research Laboratories Preclinical CRO driving smarter drug development with integrated services and scientific clarity 32Funding top 37%Innovation top 39%Product top 46%Talent bottom 49% All 7 signals ▾Fundingtop 37% Innovationtop 39% Producttop 46% Talentbottom 49% Techbottom 44% Globalbottom 29% Marketbottom 28% Funding: Raised $51.6M across 32 rounds · 32 rounds over 23 yrs (1.4/yr) Innovation: 9 product lines rank vs industry peers · Fliar Intelligence Index 32/100 | $52M | 13 mo ago | Funding Raised | 20 | Elke Lipka President and CEO | — | — | — |
| 23 | ILiAD Biotechnologies Developer of immunity-inducing vaccine for the prevention and treatment of pertussis 24Funding top 25%Moat top 36%Patents top 38%Innovation top 42% All 9 signals ▾Fundingtop 25% Moattop 36% Patentstop 38% Innovationtop 42% Newsbottom 49% Talentbottom 49% Globalbottom 36% Marketbottom 24% Techbottom 22% Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $51M | 4 mo ago | Series B | 8 | Keith Rubin Founder & CEO | — | 24 patents Patents concentrated in health & consumer products | 1 partnership |
| 24 | SAB Biotherapeutics Developer of immunotherapeutics to treat infectious and autoimmune diseases 21Funding top 25%News top 38%Tech top 46%Global bottom 37% All 8 signals ▾Fundingtop 25% Newstop 38% Techtop 46% Globalbottom 37% Moatbottom 37% Marketbottom 35% Growthbottom 32% Fin. healthbottom 26% Funding: Raised $49.0M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) News: 4 BI events in 12 mo (of 36 tracked, 7 types) · +33% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $49M | 10 mo ago | Public | 56 56 → 88 (+57%) · sector median +33% | — | 4 signals ▲33% Leadership · Earnings | — | — |
| 25 | Codagenix Developer of live-attenuated viral vaccines using proprietary SAVE technology 62Patents top 19%Moat top 21%Innovation top 24%Talent top 28% All 9 signals ▾Patentstop 19% Moattop 21% Innovationtop 24% Talenttop 28% Fundingtop 30% Marketbottom 49% Globalbottom 42% Techbottom 38% Newsbottom 27% Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $47M | 14 mo ago | Series B | 41 | — | — | 127 patents Live-attenuated viral vaccine design using codon deoptimization and recombinant virus platforms | — |
| 26 | NanoViricides Targeted antiviral therapeutics 14Funding top 26%Moat top 48%Growth bottom 40%News bottom 35% All 7 signals ▾Fundingtop 26% Moattop 48% Growthbottom 40% Newsbottom 35% Globalbottom 30% Marketbottom 29% Techbottom 24% Funding: Raised $47.0M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) Moat: Editorial + unicorn rating 5/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 14/100 | $47M | 7 mo ago | Public | 17 | — | — | — | — |
| 27 | Celdara Medical Developer of therapeutics for the treatment of multiple diseases 21Funding top 30%Talent bottom 49%Tech bottom 38%Global bottom 32% All 6 signals ▾Fundingtop 30% Talentbottom 49% Techbottom 38% Globalbottom 32% Marketbottom 28% Newsbottom 22% Funding: Raised $46.5M across 37 rounds · 37 rounds over 17 yrs (2.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 21/100 | $46M | 12 mo ago | Funding Raised | 16 16 → 19 (+19%) · sector median +33% | Jake Reder CEO | — | — | — |
| 28 | Abvacc Developer of vaccines and therapeutics to treat infectious diseases 35Funding top 30%Moat top 38%Patents top 43%Innovation top 50% All 7 signals ▾Fundingtop 30% Moattop 38% Patentstop 43% Innovationtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 31% Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $46M | 12 mo ago | Funding Raised | — | M Aman Founder | — | 6 patents Vaccines targeting bacterial toxins and cell‑wall domains for immunotherapy | — |
| 29 | Peptilogics Developer of antibiotics to target MDR bacteria 50Patents top 20%Funding top 23%Innovation top 24%Moat top 32% All 9 signals ▾Patentstop 20% Fundingtop 23% Innovationtop 24% Moattop 32% Talentbottom 49% Techbottom 48% Newsbottom 42% Globalbottom 42% Marketbottom 29% Patents: 83 patents matched (strict assignee match) · 67 filings since 2022 vs 16 in 2017-21 Funding: Raised $42.4M across 13 rounds · 13 rounds over 10 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $42M | 8 mo ago | Series B | 23 23 → 22 (-4%) · sector median +33% | Jonathan Steckbeck Founder | President | CEO | — | 83 patents Antimicrobial peptide therapeutics and AI-driven peptide drug discovery platforms | — |
| 30 | Lumos Diagnostics Provider of rapid point-of-care diagnostic test solutions 57Funding top 25%Partners top 31%News top 34%Growth top 38% All 8 signals ▾Fundingtop 25% Partnerstop 31% Newstop 34% Growthtop 38% Markettop 48% Moattop 48% Techbottom 46% Globalbottom 44% Funding: Raised $40.0M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals rank vs industry peers · Fliar Intelligence Index 57/100 | $40M | 2 mo ago | Public | 55 | — | 6 signals Contracts · Earnings · Regulatory | — | 1 partnership |
| 31 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 12 mo ago | Public | 6 | Jeffrey Meckler Chief Executive Officer | — | — | — |
| 32 | AusperBio Developer of therapies for the treatment of chronic hepatitis B and other major infectious diseases 40Funding top 26%Talent top 38%Moat top 39%Growth bottom 42% All 7 signals ▾Fundingtop 26% Talenttop 38% Moattop 39% Growthbottom 42% Marketbottom 40% Globalbottom 38% Newsbottom 24% Funding: Raised $37.0M across 4 rounds · 4 rounds over 2 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $37M | 8 mo ago | Series B | — | Guofeng Cheng Co-Founder & CEO | — | — | — |
| 33 | Altesa Biosciences Developer of drugs to treat RNA viruses 27Talent top 23%Funding top 27%Moat top 48%Global bottom 45% All 6 signals ▾Talenttop 23% Fundingtop 27% Moattop 48% Globalbottom 45% Techbottom 31% Marketbottom 22% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated Funding: Raised $35.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 27/100 | $35M | 4 mo ago | Series B | 8 | John Clerici Co-Founder | — | — | — |
| 34 | Chembio POC Diagnostics for Infectious Diseases using a proprietary immunoassay platform 60Funding top 23%Product top 32%Innovation top 38%Moat top 39% All 9 signals ▾Fundingtop 23% Producttop 32% Innovationtop 38% Moattop 39% Markettop 41% Fin. healthtop 45% Growthtop 48% Techtop 50% Globalbottom 32% Funding: Raised $33.7M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Product: 3 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 60/100 | $34M | 4 mo ago | Acquired | 337 | — | — | — | 3 launchs |
| 35 | Affinity Biosensors Developer of rapid antimicrobial susceptibility testing devices for life sciences 27Funding top 27%Moat top 31%Talent bottom 49%Patents bottom 46% All 7 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Patentsbottom 46% Innovationbottom 39% Globalbottom 36% Marketbottom 34% Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $31M | 2 mo ago | Series B | 21 | Ken Babcock CEO | — | 12 patents Rapid antimicrobial susceptibility testing via resonant mass and microchannel sensor technologies | — |
| 36 | Rational Vaccines Developer of live attenuated viral immunotherapeutic and prophylactic vaccine candidates 29Funding top 28%Moat top 38%Patents top 40%Innovation top 46% All 8 signals ▾Fundingtop 28% Moattop 38% Patentstop 40% Innovationtop 46% Talentbottom 49% Techbottom 42% Globalbottom 37% Marketbottom 25% Funding: Raised $30.6M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 8 mo ago | Series B | 18 18 → 11 (-39%) · sector median +33% | Agustin Fernandez Founder & CEO | — | 9 patents Serological SARS‑CoV‑2 diagnostics and recombinant vaccine platforms for intracellular pathogens. | — |
| 37 | Valthos Developer of AI systems for biological threat identification and countermeasure design 55Funding top 34%AI top 45%Talent bottom 49%Global bottom 33% All 4 signals ▾Fundingtop 34% AItop 45% Talentbottom 49% Globalbottom 33% Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 55/100 | $30M | 10 mo ago | Seed | — | Tess Stekelenburg Co-Founder & President | — | — | — |
| 38 | Scanogen Provider of single-molecule biosensors for cancer diagnostics 29Talent top 28%Moat top 32%Funding top 33%Patents top 35% All 9 signals ▾Talenttop 28% Moattop 32% Fundingtop 33% Patentstop 35% Innovationtop 42% Productbottom 44% Globalbottom 35% Techbottom 28% Marketbottom 21% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $29M | 10 mo ago | Funding Raised | 7 | — | — | 26 patents Biosensor and imaging technologies for rapid medical analyte detection and diagnostics | — |
| 39 | LPOXY Therapeutics Developer of therapies for infectious disease prevention 24Funding top 42%Talent bottom 49%Global bottom 25%News bottom 18% All 4 signals ▾Fundingtop 42% Talentbottom 49% Globalbottom 25% Newsbottom 18% Funding: Raised $28.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $28M | 9 mo ago | Series A | — | Larry Sutton President & Founder | — | — | — |
| 40 | Opus Genetics Developer of gene therapies to treat retinal degenerative diseases 42Patents top 29%Funding top 30%Moat top 32%Innovation top 34% All 11 signals ▾Patentstop 29% Fundingtop 30% Moattop 32% Innovationtop 34% Talenttop 38% Growthtop 47% Techtop 50% Newstop 50% Globalbottom 36% Marketbottom 31% Fin. healthbottom 28% Patents: 26 patents matched (strict assignee match) · 26 filings since 2022 vs 0 in 2017-21 Funding: Raised $23.5M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $24M | 10 mo ago | Public | 14 | Jason Menzo Co-Founder | 4 signals ▼20% Regulatory · Earnings · Funding | 26 patents Ophthalmic alpha‑adrenergic antagonist drugs for mydriasis, presbyopia, and AMD treatment | — |
| 41 | Xanadu Bio Delivery of nanoparticle system for mRNA and other payload delivery 53Funding top 37%Talent top 45%Global bottom 25% All 3 signals ▾Fundingtop 37% Talenttop 45% Globalbottom 25% Funding: Raised $23.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 53/100 | $23M | 10 mo ago | Series B | 5 | Bruce Turner Co-Founder & CEO | — | — | — |
| 42 | eradivir Developer of immunotherapies for the treatment of infectious diseases 22Funding top 32%Talent top 38%Growth top 45%Moat bottom 38% All 7 signals ▾Fundingtop 32% Talenttop 38% Growthtop 45% Moatbottom 38% Globalbottom 29% Techbottom 24% Marketbottom 23% Funding: Raised $20.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 22/100 | $20M | 8 mo ago | Series A | 6 | Martin Low Co-Founder & CEO | — | — | — |
| 43 | Mucommune R&D firm advancing immunology, drug delivery, and mucosal biology innovations 9Funding top 33%Moat bottom 49%Talent bottom 45%Patents bottom 35% All 7 signals ▾Fundingtop 33% Moatbottom 49% Talentbottom 45% Patentsbottom 35% Globalbottom 35% Marketbottom 20% Innovationbottom 17% Funding: Raised $19.4M across 13 rounds · 13 rounds over 10 yrs (1.3/yr) Moat: Editorial + unicorn rating 1/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 9/100 | $19M | 9 mo ago | Funding Raised | 12 | Sam Lai Founder | — | 6 patents Patents concentrated in chemistry & materials | — |
| 44 | Lighthouse Pharma Developer of therapeutics for neurology and infectious diseases 11Funding top 46%Talent bottom 49%Tech bottom 45%Global bottom 25% All 5 signals ▾Fundingtop 46% Talentbottom 49% Techbottom 45% Globalbottom 25% Marketbottom 18% Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $15M | 1 mo ago | Series A | 4 | Casey Lynch Chief Executive Officer | — | — | 1 job opening |
| 45 | Seek Labs Developer of a technology for the treatment and diagnostics of infectious diseases. 53AI top 15%Patents top 27%Innovation top 28%Moat top 32% All 9 signals ▾AItop 15% Patentstop 27% Innovationtop 28% Moattop 32% Fundingtop 33% Talentbottom 49% Techbottom 44% Globalbottom 31% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) Patents: 48 patents matched (strict assignee match) · 30 filings since 2022 vs 12 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $14M | 3 mo ago | Series B | 27 | Jared Bauer CEO | — | 48 patents Molecular diagnostics and CRISPR-based nucleic acid testing for veterinary disease detection | — |
| 46 | Alphyn Biologics Developer of therapeutics for severe and common skin diseases 27Patents top 28%Moat top 32%Innovation top 33%Funding top 37% All 7 signals ▾Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 37% Techbottom 43% Globalbottom 40% Marketbottom 16% Patents: 30 patents matched (strict assignee match) · 21 filings since 2022 vs 9 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 30 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $13M | 6 mo ago | Series B | 3 | — | — | 25 patents Topical antibacterial skin treatments using croton lechleri-derived pharmaceutical compositions | — |
| 47 | Jaguar Health Developing gastrointestinal products for human prescription use and animals 50Product top 14%Funding top 24%Innovation top 34%Growth top 43% All 11 signals ▾Producttop 14% Fundingtop 24% Innovationtop 34% Growthtop 43% Talentbottom 49% Marketbottom 48% Fin. healthbottom 48% Moatbottom 45% Newsbottom 41% Techbottom 33% Globalbottom 32% Product: 4 distinct product lines · Company stage: Public Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $12M | 5 mo ago | Public | 46 46 → 35 (-24%) · sector median +33% | Lisa Conte Founder & CEO | 3 signals ▼88% Earnings · Announcements | — | 1 launch · 1 partnership |
| 48 | Centivax Provider of drug discovery services 55Growth top 25%News top 28%Funding top 32%Patents top 32% All 9 signals ▾Growthtop 25% Newstop 28% Fundingtop 32% Patentstop 32% Innovationtop 40% Moattop 47% Globalbottom 40% Techbottom 39% Marketbottom 29% Growth: Fresh capital in last 24 mo News: 5 BI events in 12 mo (of 5 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $10M | 2 mo ago | Series A | 19 | — | 5 signals Funding · Capital raise | 39 patents Peptide-derived therapeutic antibodies and low-dose vaccine formulations targeting viral antigens | — |
| 49 | Curative Provider of self collecting COVID-19 testing centers listing platform 48Tech top 20%Innovation top 31%Patents top 33%News top 39% All 11 signals ▾Techtop 20% Innovationtop 31% Patentstop 33% Newstop 39% Fundingtop 42% Growthtop 42% Producttop 49% Moatbottom 44% Marketbottom 43% Globalbottom 33% Fin. healthbottom 14% Tech: 40 technologies across 6/8 capability areas · Cloud: Amazon Web Services, Cloudflare Innovation: 10 patents (top 47% of patent-holders) · 8 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 7 mo ago | Series B | 2,251 | — | — | 10 patents Molecular diagnostics: nucleic acid purification, sample collection kits, and infection/immunity testing devices. | 1 award |
| 50 | Pearl Diagnostics Foundation focused on detection and prevention of fungal infections 13Funding top 35%Talent bottom 49%Global bottom 32%Market bottom 20% All 4 signals ▾Fundingtop 35% Talentbottom 49% Globalbottom 32% Marketbottom 20% Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 13/100 | $4M | 3 mo ago | Series B | 6 | Kieren Marr Founder & CEO | — | — | — |
Top 12 Infectious Diseases companies in United States
#1
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Public · Vancouver, Washington · founded 2002 · 12 employees
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 17%Growth
top 35%Patents
top 36%Innovation
top 44%Moat
bottom 49%Global
bottom 36%Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) · Last round Post IPO (Mar 2026)
Growth: Fresh capital in last 24 mo
Patents: 107 patents matched (strict assignee match) · 25 filings since 2022 vs 49 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 4k LinkedIn followers · 65 engagements/post (4.5× cohort median)
Activity (LinkedIn): 1 partnerships (incl. Natera) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
Investors
Cool Blue Capital, Centrecourt Asset Management, 4-Good Ventures
Tech stack
Amazon Web ServicesApache Http ServerApple Icloud MailBootstrapFancyboxGoogle Analytics
#2
Public · Emeryville, California · founded 2000 · 33 employees$219.5Mraised▾
Public · Emeryville, California · founded 2000 · 33 employees
Developer of eye care and wound care products. The company's products include Avenova An antimicrobial lid and lash solution for eye care, PhaseOne and NeutroPhase a wound care products using hypochlorous acid for cleansing, irrigation, and treating injuries.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 21%Product
top 35%News
top 46%Talent
bottom 49%Moat
bottom 44%Market
bottom 43%Funding: Raised $220M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) · Last round Post IPO (Jan 2026)
Product: 0 product launch events in 12 mo · Company stage: Public
News: 5 BI events in 12 mo (of 130 tracked, 11 types) · -62% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Jan 2026Post IPO$134M
- Aug 2025Post IPO$6M
- Mar 2024Post IPO$665K
- Sep 2022Post IPO—
Founders & team
Investors
Wealthking Investments, TRITON FUNDS, Framework Ventures, Tether, R01 Fund, City Hill
Tech stack
WordpressMysqlPhpYoast SeoNginxPrettyphoto
#3
Series A · Philadelphia, Pennsylvania · founded 2022$54Mraised▾
Series A · Philadelphia, Pennsylvania · founded 2022
Developer of gene therapy medicines for neurological diseases. The company leverages precision delivery through Adeno-Associated Virus to target specific cells and tissues, to improve the lives of patients suffering from various central nervous system disorders.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Moat
top 31%Talent
bottom 49%Market
bottom 40%Global
bottom 36%Funding: Raised $54.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- May 2026Series A$97M
- May 2024Series A$54M
Founders & team
Investors
8VC, DCVC, Children's Hospital of Philadelphia, Ben Franklin Technology Partners, Gaingels, Modi Ventures
#4
Public · Menlo Park, California · founded 2017 · 35 employees$92Mraised▾
Public · Menlo Park, California · founded 2017 · 35 employees
Developer of drugs for treating infectious disease. The company is developing novel small molecule therapeutics, designing and executing clinical trials on experimental treatments, and navigating the regulatory approval process for new medicines.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 19%Talent
top 38%Moat
top 48%Market
bottom 42%Global
bottom 32%News
bottom 24%Funding: Raised $92.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Post IPO (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers · 50 engagements/post (3.4× cohort median)
Activity (LinkedIn): 1 partnerships (incl. GSK for TB) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$40M
- Jan 2022Series B$80M
- Nov 2019Series A$12M
Founders & team
Investors
Mountain Group Partners, Adjuvant Capital, Brii Biosciences, BioRock Ventures, RA Capital Management, BVF Partners
#5
Public · Cambridge, Massachusetts · founded 2010 · 1312 employees$2.8Braised▾
Public · Cambridge, Massachusetts · founded 2010 · 1312 employees
Developer of mRNA-based therapeutics for a wide range of diseases. The company produces human proteins, antibodies, or vaccines inside patient cells, which are in turn active intracellularly or secreted. The company is also developing vaccines in different disease areas such as infectious diseases, cancer, rare diseases, and COVID-19.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Tech
top 11%Funding
top 15%Market
top 22%Partners
top 25%Talent
top 25%News
top 31%Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses · Devops: Envoy, Nginx
Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) · Last round Grant (prize money) (Jan 2025)
Market: 1,312 employees (top 7% of Sustainability Tech) · Revenue ~$1.9B · Top-5,000,000 web property
Audience (LinkedIn): 791k LinkedIn followers — 72.3% of this cohort's audience
Funding rounds
- Jan 2025Grant (prize money)$590M
- Jul 2024Grant (prize money)$176M
- Oct 2020Grant (prize money)$56M
- May 2020Post IPO—
Founders & team
Investors
ADIA, BB Biotech, Julius Baer, Sequoia Capital, Fidelity Investments, Viking Global Investors
Tech stack
AccessibeAmazon CloudfrontAmazon SesAmazon Web ServicesApolloApple Icloud Mail
#6
Series B · Santa Barbara, California · founded 2006 · 21 employees$31.3Mraised▾
Series B · Santa Barbara, California · founded 2006 · 21 employees
Developer of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 27%Moat
top 31%Talent
bottom 49%Patents
bottom 46%Innovation
bottom 39%Global
bottom 36%Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Mar 2026Post IPO$2.3M
- Nov 2024Series B$14.4M
- Jun 2024Series A$3.7M
- Nov 2023Series A$2.4M
Founders & team
Investors
National Science Foundation
#7
Public · Carlsbad, California · founded 2017 · 55 employees$40Mraised▾
Public · Carlsbad, California · founded 2017 · 55 employees
Provider of rapid point-of-care diagnostic test solutions. It offers FebriDx a rapid, fingerstick blood test intended to help differentiate between bacterial vs non-bacterial acute respiratory infections and ViraDx a rapid POC test that can simultaneously test for respiratory viruses like COVID-19 and Influenza A/B.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 25%Partners
top 31%News
top 34%Growth
top 38%Market
top 48%Moat
top 48%Funding: Raised $40.0M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Post IPO (Mar 2026)
Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
News: 6 BI events in 12 mo (of 21 tracked, 8 types) · +0% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 10k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. CG Life) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$20M
- Oct 2020Series B$25M
- Feb 2020Series A$15M
Investors
Ellerston Capital, Perennial, Planet Innovation, AirTree
Tech stack
AkismetBootstrapCloudflareCloudflare Browser InsightsContact Form 7Google Analytics
#8
Series B · New York City, New York · founded 2012 · 8 employees$51.2Mraised▾
Series B · New York City, New York · founded 2012 · 8 employees
Developer of immunity-inducing vaccine for the prevention and treatment of pertussis. Its lead candidate BPZE1, a live attenuated Bordetella pertussis (BP) vaccine claims to induce sterilizing mucosal immunity and long-lasting protection against pertussis disease. The candidate is nasally administered BPZE to induce both mucosal and systemic potent immune responses.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 25%Moat
top 36%Patents
top 38%Innovation
top 42%News
bottom 49%Talent
bottom 49%Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) · Last round Series B (Feb 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents · Soonicorn
Patents: 24 patents matched (strict assignee match) · 18 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. hVIVO) announced in 12 mo
Funding rounds
- Feb 2026Series B$115M
- Dec 2023Series A—
- Sep 2022Series A$42.8M
- May 2022Grant (prize money)$972.1K
Founders & team
Investors
Livent, Knottpartners, NIH, HHS, RA Capital Management, Janus Henderson Investors
#9
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees$187.8Mraised▾
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees
Developer of whole-parasite malaria vaccines for infectious diseases. The company is developing protective vaccines against malaria and plasmodium falciparum infection in humans.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 23%Patents
top 33%Moat
top 41%Innovation
top 46%Growth
top 47%Market
bottom 44%Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 1/10 · IP moat: 134 patents
Funding rounds
- Sep 2025Grant (prize money)$2M
- Sep 2025Grant (prize money)$5.9M
- Jul 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$988.8K
Investors
NIAID, Gates, HHS
Tech stack
Animate.CssBootstrapContact Form 7Core-JsFont AwesomeGoogle Analytics
#10
Acquired · Medford, Oregon · founded 1986 · 337 employees$33.7Mraised▾
Acquired · Medford, Oregon · founded 1986 · 337 employees
Chembio Diagnostics, Inc. specializes in proprietary rapid diagnostic tests. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) - a chromatographic immunoassay technology, which the company claims offers offers significant advantages over Lateral Flow (LF) technology.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 23%Product
top 32%Innovation
top 38%Moat
top 39%Market
top 41%Fin. health
top 45%Funding: Raised $33.7M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) · Last round Grant (prize money) (Feb 2026)
Product: 3 distinct product lines · Company stage: Acquired
Innovation: 3 product lines
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Feb 2026Grant (prize money)$1.8M
- Sep 2019Conventional Debt$20M
- Feb 2011Grant (prize money)—
- Feb 2011Grant (prize money)$2.8M
Investors
Perceptive Advisors, HHS, CARB-X
Tech stack
WordpressMysqlPhpMaterial Design LiteAnimate.CssWpbakery
#11
Series D · San Clemente, California · founded 2013 · 13 employees$110.8Mraised▾
Series D · San Clemente, California · founded 2013 · 13 employees
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections. The company lead product VT-X7 is for Periprosthetic joint infection and targets chronic bacterial PJI. Another drug candidate A-103 is for fungal PJI. The company offers its drug-device combination product for antibiotic therapy for local delivery to treat infected joint prostheses like bacterial and fungal infections for joints like shoulder, knee, and hip.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 19%Moat
top 38%Talent
bottom 49%Global
bottom 37%Market
bottom 31%Funding: Raised $111M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series D (Oct 2025)
Moat: Editorial + unicorn rating 5/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 9 hiring posts in 12 mo (public) · momentum +9 · hiring: Area Vice President (East/West), Account Manager
Funding rounds
- Oct 2025Series D$15.6M
- May 2024Series D$50M
- Sep 2023Series C$23M
- Mar 2022Series B$30M
Founders & team
Investors
Gideon Strategic Partners, Johnson & Johnson Innovation – JJDC, Prism Ventures, Medvest Capital, HM Venture Partners, Huimei Capital
#12
Series B · College Park, Georgia · founded 2020 · 8 employees$35Mraised▾
Series B · College Park, Georgia · founded 2020 · 8 employees
Developer of drugs to treat RNA viruses. The lead product of the company ALT-2023 is a broadly active nucleoside analog to address most Enteroviruses & Flaviviruses. Other drug candidate includes Vapendavir a capsid inhibitor with potent activity across Rhinovirus, Influenza, and Respiratory Syncytial Virus (RSV).
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Talent
top 23%Funding
top 27%Moat
top 48%Global
bottom 45%Tech
bottom 31%Market
bottom 22%Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Funding: Raised $35.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series B (Feb 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Feb 2026Series B$75M
- Dec 2022Series B$35M
Founders & team
Investors
Forbion, Sanofi, Medicxi, Pitango, Atlantic Partners, GRA Venture Fund
Funding & investor landscape
$29.7Btotal disclosed funding
614companies funded
3,404disclosed rounds
8rounds last 90 days
Most active investors
Gates23 rounds
Notable founders
Justin Hall
CEO · NovaBay Pharmaceuticals
P Ghoroghchian
CEO · Latus
Eric Easom
Co-Founder & CEO & President · AN2 Therapeutics
Michael Alley
Co-Founder · AN2 Therapeutics
Robert Langer
Co-Founder · Moderna
Kenneth Chien
Co-Founder · Moderna
Ken Babcock
CEO · Affinity Biosensors
Keith Rubin
Founder & CEO · ILiAD Biotechnologies
David Thompson
Chairman and Chief Executive Officer · Osteal Therapeutics
John Clerici
Co-Founder · Altesa Biosciences
Seth Rudnick
Co-Founder · Altesa Biosciences
Casey Lynch
Chief Executive Officer · Lighthouse Pharma
Prism market signals · United States · country-scoped Prism corpus, 1,265,774 docs
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
RESEARCH SIGNALS · United States
How research on Diagnostics is moving in the United States
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,526 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 53% → 57% across 2008–2026.
top research entities
- Harvard University330
- Johns Hopkins University318
- Heidelberg University249
- Massachusetts General Hospital214
- The University of Texas MD Anderson Cancer Center191
leading researchers
Gerald J. Kost · Liya Xu · Charlotte A. Gaydos · Andrew A. Davis · Yu‐Hsiang Hsieh · Stephanie N. Shishido · Helen J. Huang · David T. Wong
▲
Breakthroughs1,879 · 22%
▲ 18%→24% share
▲1.3× share momentum1 median citations56% since 2021mostly methods-led
Liquid biopsy breakthrough research is surging — U.S. papers tripled from 125 to 427, now anchoring 24% of diagnostics breakthroughs.
rising sub-themes (early→recent)
- Liquid biopsy125→427
- Biopsy15→114
- Biomarker17→103
- Point-of-care testing112→195
- Cancer67→146
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→58 · Coronavirus disease 2019 (COVID-19) 0→45 · Methylation 0→33
Landmark Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells · 1,071 cites
◆
Advancements3,687 · 43%
▲ 39%→45% share
▲1.2× share momentum2 median citations54% since 2021mostly empirical
Cancer-focused advancement research is intensifying — liquid biopsy papers quadrupled (183→739) alongside emerging precision oncology and glioblastoma sub-topics.
rising sub-themes (early→recent)
- Liquid biopsy183→739
- Biopsy42→285
- Biomarker55→208
- Cancer115→260
- Oncology57→183
Newly emergingTranscriptome 0→19 · Glioblastoma 0→18 · Precision oncology 0→16
Landmark Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies · 5,005 cites
▼
Concerns2,138 · 25%
▼ 32%→22% share
▼0.7× share momentum7 median citations45% since 2021mostly empirical
Concern-flagged diagnostics research is cooling in share (32%→22%) despite liquid biopsy papers nearly quadrupling (67→239), signaling shifting risk focus.
rising sub-themes (early→recent)
- Liquid biopsy67→239
- Biopsy17→99
- Biomarker28→86
- Coronavirus disease 2019 (COVID-19)1→44
- Cancer55→92
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→40 · Extracellular vesicles 0→21 · Glioma 0→11
Landmark Point-of-Care Diagnostics for Global Health · 1,066 cites
RESEARCH HOTSPOTS · United States
Where diagnostics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston642 · +0.40
New York419 · +0.36
SF Bay Area370 · +0.36
Los Angeles278 · +0.50
Philadelphia194 · +0.30
Chicago182 · +0.40
Seattle166 · +0.34
San Diego165 · +0.43
Atlanta127 · +0.28
Ann Arbor108 · +0.47
PATENT SIGNAL · United States
Who's filing diagnostics patents in the United States
United States diagnostics patent filing is accelerating — 418 filings from 196 assignees (2016–2025), led by Detect, UNIV Leland Stanford Junior, Washington University ST Louis; annual filings 13→55.
418 filings196 assigneespeak 67/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Detect42
- UNIV Leland Stanford Junior33
- Washington University ST Louis20
- Nuclein19
- Texas A & M UNIV SYS19
- UNIV California19
- Tempus LABS18
- New England Biolabs18
Common questions
How many Infectious Diseases companies are there in United States?
Radar tracks 1010 indexable Infectious Diseases companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Infectious Diseases companies in United States?
The Infectious Diseases companies in United States on this list have raised a combined $29.7B in disclosed equity funding across 614 funded companies.
Which is the highest-funded Infectious Diseases company in United States?
Moderna is the highest-funded Infectious Diseases company in United States, with $2.8B in disclosed equity funding.
How many Infectious Diseases companies in United States are funded?
614 of the 1010 Infectious Diseases companies in United States on this list have disclosed at least one equity funding round.
How many Infectious Diseases unicorns are there in United States?
1 Infectious Diseases company in United States on this list is valued at $1B or more.
Who are the top investors in United States Infectious Diseases companies?
The most active investors in United States Infectious Diseases companies on this list include HHS, NIH, National Science Foundation, Military Health, NIAID.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.